Systematic Review And Meta-Analysis Of Psoriasis Treatments.

NCT01425138

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.

- Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Observational studies


- Trials that did not report the Physician's Global Assessment (PGA),


- Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Advanced Information
Descriptive Information
Brief Title Systematic Review And Meta-Analysis Of Psoriasis Treatments.
Official Title Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis
Brief Summary This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.
Detailed Description This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Moderate-to-severe plaque psoriasis published trials.
Condition Psoriasis
Intervention Not Provided
Study Groups/Cohorts Psoriasis
Published data on moderate-to-severe plaque psoriasis.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: November 29, 2018)
1
Original Estimated Enrollment
 (submitted: August 26, 2011)
0
Actual Study Completion Date June 2011
Actual Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.
  • Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion Criteria:

Observational studies

  • Trials that did not report the Physician's Global Assessment (PGA),
  • Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01425138
Other Study ID Numbers A3921142
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators University of Connecticut School of Pharmacy and Hartford Hospital
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2018